Findings

What do systematic reviews say?

21 questions · 32 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 14 · 43.8%Very low 18 · 56.3%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Risk‐reducing salpingo‐oophorectomy (RRSO) vs no RRSO

Overall survival: RRSO alone vs RRSO and RRM

1 finding from 1 review

Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations 2018 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Risk‐reducing salpingo‐oophorectomy (RRSO) vs no RRSO

Overall survival: RRSO and RRM vs no RRSO

It is very uncertain whether risk‐reducing salpingo‐oophorectomy (RRSO) changes overall survival: RRSO and RRM vs no RRSO compared with no RRSO (very low certainty).

1 finding from 1 review

Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations 2018 · Cochrane Headline outcomes only
HR 0.14 [0.02, 0.98]
1 study · 261 participants
Very low

Risk‐reducing salpingo‐oophorectomy (RRSO) vs no RRSO

Breast Cancer‐related Death

2 findings from 1 review

Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations 2018 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported
Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 722 participants
Very low

Risk‐reducing salpingo‐oophorectomy (RRSO) vs no RRSO

Overall survival: BRCA1 or BRCA2

It is very uncertain whether risk‐reducing salpingo‐oophorectomy (RRSO) changes overall survival: BRCA1 or BRCA2 compared with no RRSO (very low certainty).

1 finding from 1 review

Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations 2018 · Cochrane Headline outcomes only
HR 0.32 [0.19, 0.54]
3 studies · 2548 participants
Very low

Risk‐reducing salpingo‐oophorectomy (RRSO) vs no RRSO according to BRCA mutation status

HGSC mortality: BRCA1 only

It is very uncertain whether risk‐reducing salpingo‐oophorectomy (RRSO) changes HGSC mortality: BRCA1 only compared with no RRSO according to BRCA mutation status (very low certainty).

1 finding from 1 review

Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations 2018 · Cochrane Headline outcomes only
HR 0.1 [0.02, 0.41]
2 studies · 1983 participants
Very low

Risk‐reducing salpingo‐oophorectomy (RRSO) vs no RRSO according to BRCA mutation status

HGSC mortality: BRCA2 only

1 finding from 1 review

Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations 2018 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1983 participants
Very low

Risk‐reducing salpingo‐oophorectomy (RRSO) vs no RRSO according to BRCA mutation status

Breast cancer mortality: BRCA1 only

It is very uncertain whether risk‐reducing salpingo‐oophorectomy (RRSO) changes breast cancer mortality: BRCA1 only compared with no RRSO according to BRCA mutation status (very low certainty).

1 finding from 1 review

Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations 2018 · Cochrane Headline outcomes only
HR 0.45 [0.3, 0.67]
4 studies · 2203 participants
Very low

Risk‐reducing salpingo‐oophorectomy (RRSO) vs no RRSO according to BRCA mutation status

Breast cancer mortality: BRCA2 only

It is very uncertain whether risk‐reducing salpingo‐oophorectomy (RRSO) changes breast cancer mortality: BRCA2 only compared with no RRSO according to BRCA mutation status (very low certainty).

1 finding from 1 review

Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations 2018 · Cochrane Headline outcomes only
HR 0.88 [0.42, 1.87]
3 studies · 5882 participants
Very low

Risk‐reducing salpingo‐oophorectomy (RRSO) vs no RRSO according to BRCA mutation status

Quality of life (ovarian cancer risk perception): BRCA1 only

1 finding from 1 review

Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 98 participants
Very low

Risk‐reducing salpingo‐oophorectomy (RRSO) vs no RRSO

Incidence of fractures

4 findings from 1 review

Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations 2018 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported
Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations 2018 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported
Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations 2018 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Show 1 more finding

Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations 2018 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Risk‐reducing salpingo‐oophorectomy (RRSO) vs no RRSO

HGSC mortality: BRCA1 or BRCA2

It is very uncertain whether risk‐reducing salpingo‐oophorectomy (RRSO) changes HGSC mortality: BRCA1 or BRCA2 compared with no RRSO (very low certainty).

1 finding from 1 review

Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations 2018 · Cochrane Headline outcomes only
HR 0.06 [0.02, 0.17]
3 studies · 2534 participants
Very low

Risk‐reducing salpingo‐oophorectomy (RRSO) vs no RRSO

Severe adverse events

4 findings from 1 review

Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations 2018 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported
Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations 2018 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported
Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations 2018 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Show 1 more finding

Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations 2018 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Risk‐reducing salpingo‐oophorectomy (RRSO) vs no RRSO

Overall survival

2 findings from 1 review

Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations 2018 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported
Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations 2018 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Risk‐reducing salpingo‐oophorectomy (RRSO) vs no RRSO

HGSC mortality

2 findings from 1 review

Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations 2018 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported
Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations 2018 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Risk‐reducing salpingo‐oophorectomy (RRSO) vs no RRSO

Breast cancer mortality: ≤ 50 years

It is very uncertain whether risk‐reducing salpingo‐oophorectomy (RRSO) changes breast cancer mortality: ≤ 50 years compared with no RRSO (very low certainty).

2 findings from 1 review

Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations 2018 · Cochrane Headline outcomes only
HR 0.78 [0.55, 1.09]
3 studies · 4566 participants
Very low
Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations 2018 · Cochrane Headline outcomes only
HR 0.49 [0.08, 2.9]
2 studies · 444 participants
Very low

Risk‐reducing salpingo‐oophorectomy (RRSO) vs no RRSO

Breast cancer mortality: > 50 years

It is very uncertain whether risk‐reducing salpingo‐oophorectomy (RRSO) changes breast cancer mortality: > 50 years compared with no RRSO (very low certainty).

2 findings from 1 review

Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations 2018 · Cochrane Headline outcomes only
HR 1.27 [0.67, 2.38]
3 studies · 4566 participants
Very low
Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations 2018 · Cochrane Headline outcomes only
HR 1.36 [0.68, 2.75]
2 studies · 444 participants
Very low

Risk‐reducing salpingo‐oophorectomy (RRSO) vs no RRSO

Breast cancer mortality: BRCA1 or BRCA

It is very uncertain whether risk‐reducing salpingo‐oophorectomy (RRSO) changes breast cancer mortality: BRCA1 or BRCA compared with no RRSO (very low certainty).

1 finding from 1 review

Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations 2018 · Cochrane Headline outcomes only
HR 0.58 [0.39, 0.88]
7 studies · 7198 participants
Very low

Risk‐reducing salpingo‐oophorectomy (RRSO) vs no RRSO

Quality of life (ovarian cancer risk perception): BRCA1 or BRCA2

1 finding from 1 review

Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 200 participants
Very low

Risk‐reducing salpingo‐oophorectomy (RRSO) vs no RRSO

Quality of life (breast cancer risk perception): BRCA1 or BRCA2

1 finding from 1 review

Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 200 participants
Very low

Risk‐reducing salpingo‐oophorectomy (RRSO) vs no RRSO according to BRCA mutation status

Overall survival: BRCA1 only

It is very uncertain whether risk‐reducing salpingo‐oophorectomy (RRSO) changes overall survival: BRCA1 only compared with no RRSO according to BRCA mutation status (very low certainty).

1 finding from 1 review

Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations 2018 · Cochrane Headline outcomes only
HR 0.3 [0.17, 0.52]
3 studies · 2548 participants
Very low